HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

L-BLP25: a peptide vaccine strategy in non small cell lung cancer.

Abstract
MUC1 is a mucinous glycoprotein which is overexpressed and under or aberrantly glycosylated in many human malignancies. MUC1 is associated with cellular transformation and can confer resistance to genotoxic agents. L-BLP25 is a peptide vaccine strategy that targets the exposed core peptide of MUC1. In preclinical studies, L-BLP25 induced a cellular immune response characterized by T-cell proliferation in response to MUC1 and production of IFN-gamma. Phase I and II trials have established the dose and schedule of the vaccine as well as its excellent safety profile. A randomized phase II trial of maintenance L-BLP25 versus best supportive care in patients with stage IIIB/IV non-small cell lung cancer who experienced clinical benefit from initial therapy has been reported. Updated survival analysis of this trial continues to show a strong survival trend in favor of L-BLP25 (median survival, 30.6 versus 13.3 months) in a subgroup of patients with locoregional stage IIIB disease. These promising results will be tested in a phase III trial of L-BLP25 versus placebo in patients with stage III non-small cell lung cancer after response to primary chemoradiotherapy.
AuthorsRandeep Sangha, Charles Butts
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 13 Issue 15 Pt 2 Pg. s4652-4 (Aug 01 2007) ISSN: 1078-0432 [Print] United States
PMID17671159 (Publication Type: Journal Article, Review)
Chemical References
  • Cancer Vaccines
  • L-BLP25
  • Membrane Glycoproteins
  • Mucin-1
Topics
  • Animals
  • Cancer Vaccines (therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (therapy)
  • Clinical Trials as Topic
  • Humans
  • Lung Neoplasms (therapy)
  • Membrane Glycoproteins (therapeutic use)
  • Mucin-1 (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: